


ORIGINAL ARTICLE

Augmented antitumor activity of 5-fluorouracil by double knockdown of *MDM4* and *MDM2* in colon and gastric cancer cells

Mamiko Imanishi¹ | Yoshiyuki Yamamoto¹ | Xiaoxuan Wang¹ | Akinori Sugaya² | Mitsuaki Hirose³ | Shinji Endo^{1,4} | Yukikazu Natori⁵ | Kenji Yamato¹  | Ichinosuke Hyodo¹

¹Department of Gastroenterology and Hepatology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan

²Department of Gastroenterology, Kasumigaura Medical Center, Tsuchiura, Japan

³Department of Gastroenterology, Tsuchiura Clinical Education and Training Center, University of Tsukuba Hospital, Tsuchiura, Japan

⁴Department of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo, Japan

⁵RNAi Company Ltd., Bunkyo-ku, Japan

Correspondence

Kenji Yamato, Department of Gastroenterology and Hepatology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Email: yamato@md.tsukuba.ac.jp

Funding information

Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan to H.I. (grant number 26460624).

Inactivation of the *TP53* tumor suppressor gene is essential during cancer development and progression. Mutations of *TP53* are often missense and occur in various human cancers. In some fraction of wild-type (wt) *TP53* tumors, p53 is inactivated by upregulated murine double minute homolog 2 (*MDM2*) and *MDM4*. We previously reported that simultaneous knockdown of *MDM4* and *MDM2* using synthetic DNA-modified siRNAs revived p53 activity and synergistically inhibited in vitro cell growth in cancer cells with wt *TP53* and high *MDM4* expression (wt*TP53*/high*MDM4*). In the present study, *MDM4*/*MDM2* double knockdown with the siRNAs enhanced 5-fluorouracil (5-FU)-induced p53 activation, arrested the cell cycle at G₁ phase, and potentiated the antitumor effect of 5-FU in wt*TP53*/high*MDM4* human colon (HCT116 and LoVo) and gastric (SNU-1 and NUGC-4) cancer cells. Exposure to 5-FU alone induced *MDM2* as well as p21 and PUMA by p53 activation. As p53-*MDM2* forms a negative feedback loop, enhancement of the antitumor effect of 5-FU by *MDM4*/*MDM2* double knockdown could be attributed to blocking of the feedback mechanism in addition to direct suppression of these p53 antagonists. Intratumor injection of the *MDM4*/*MDM2* siRNAs suppressed in vivo tumor growth and boosted the antitumor effect of 5-FU in an athymic mouse xenograft model using HCT116 cells. These results suggest that a combination of *MDM4*/*MDM2* knockdown and conventional cytotoxic drugs could be a promising treatment strategy for wt*TP53*/high*MDM4* gastrointestinal cancers.

KEYWORDS

5-fluorouracil, colon cancer, gastric cancer, *MDM4*, p53

1 | INTRODUCTION

5-Fluorouracil (5-FU) is a key drug in the treatment of colon and gastric cancers. Various combination therapies have been developed and improved survival. However, survival duration remains short,

and cure with chemotherapy is rarely expected.¹⁻⁵ To circumvent such problems, new therapeutic strategies are needed.

In human cancers, the tumor protein (*TP53*) tumor suppressor gene is often inactivated by missense mutation, or its function is suppressed by enhanced expression of oncogenes such as murine

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2018 The Authors. *Cancer Science* published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

double minute 2 (*MDM2*) and *MDM4*.⁶⁻⁸ *MDM2* and its complex with *MDM4* destabilizes p53 through binding and ubiquitin-dependent protein degradation.^{9,10} *MDM4* can also repress p53 transcriptional activity by directly binding to the transactivating domain.^{11,12}

Studies have shown that reactivation of wild-type (wt) *TP53* by inhibiting *MDM2*-p53 interaction or knockdown of *MDM2* and *MDM4* induces cell cycle arrest and apoptotic cell death, inhibiting tumor growth in tumors carrying wt*TP53*.^{6,13-19} Thus, *MDM2* and *MDM4* are ideal targets for cancer therapy in such tumors. Various kinds of small molecular compounds and peptides inhibiting *MDM2* function have been developed.^{6,18,20,21} Among them, idasanutlin has been shown to be an effective treatment in some clinical studies of patients with malignant lymphomas and acute myeloblastic leukemias.²²⁻²⁴

A previous study reported that cultured tumor cells with wt*TP53* can be divided into 2 types: high *MDM2* expressers and high *MDM4* expressers.¹⁶ The former expresses a high level of *MDM2* and a very low level of *MDM4*, whereas the latter expresses a high level of *MDM4* and an intermediate level of *MDM2*. Knockdown of either *MDM4* or *MDM2* alone using synthetic siRNAs with DNA-substituted seed arms (chi*MDM4*, chi*MDM2*) specifically suppressed the growth of high *MDM4* expresser cancer cells, whereas only *MDM2* knockdown but not *MDM4* knockdown suppressed that of high *MDM2* expresser cancer cells. Simultaneous knockdown of *MDM4* and *MDM2* synergistically inhibited the growth of high *MDM4* expresser cancer cells.

Overexpression or amplification of *MDM4* has been found in 19%-49% and 43% of colon and gastric cancers, respectively, whereas those of *MDM2* have been reported in 17.3% and 32.7%-41.8% of colon and gastric cancers, respectively.²⁵⁻²⁹ Therefore, reactivation of wt*TP53* by chi*MDM4* and chi*MDM2* could be used for the treatment of these cancers. In the present study, the effects of double knockdown of *MDM4* and *MDM2* using chi*MDM4* and chi*MDM2* on the antitumor activity of 5-FU in colon and gastric cancer cells with wt*TP53* and high *MDM4* (wt*TP53*/high*MDM4*) were investigated. In vivo antitumor activity of chi*MDM4* plus chi*MDM2* (chi*MDM4*/chi*MDM2*) and a combination of chi*MDM4*/chi*MDM2* with 5-FU were also explored.

2 | MATERIALS AND METHODS

2.1 | Cell culture

Four tumor cell lines with wt*TP53* were used: HCT116 colon cancer, LoVo colon cancer, SNU-1 gastric cancer, and NUGC-4 gastric cancer. The HCT116 cell line was purchased from Horizon Discovery (Cambridge, UK). LoVo and SNU-1 cell lines were purchased from ATCC (Rockville, MD, USA). The NUGC-4 cell line was obtained from the Riken BioResource Center Cell Bank (Tsukuba, Japan). HCT116, SNU-1, and NUGC-4 cells were cultured in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FBS (Nihon Bioreagents, Tokyo, Japan). LoVo cells were cultured in Ham's F-12 nutrient mixture medium (Sigma-Aldrich) with 10% FBS.

5-Fluorouracil was purchased from Kyowa Hakko Kirin (Tokyo, Japan). Nutlin-3 was purchased from Calbiochem (San Diego, CA, USA).

2.2 | Small interfering RNAs and transfection

Sequences of DNA-modified siRNAs used in this study were: chimera Control (chiControl, chiCtrl) sense strand, 5'-GUACCGCAGCAGUCAttcgtatc-3'; chiCtrl antisense strand, 5'-tacgaaUGACGUGCGGUACGU-3'; chi*MDM2* sense strand, 5'-CAGCCAUCAACU Uctagtagc-3'; chi*MDM2* antisense strand, 5'-tactagAAGUUGAUG GCUGAG-3'; chi*MDM4* sense strand, 5'-CCCUCUCUAUGAUatg ctaag-3'; chi*MDM4* antisense strand, 5'-tagcataUCAUAGAGAGGG CU-3'; chiCtrl (in vivo) sense strand, 5'-gtaGUACCGCAGUCAttc tc-3'; and chiCtrl (in vivo) antisense strand, 5'-gaaUGACGUGCGGUAC tacGU-3' (capital letters, ribonucleotides; small letters, deoxynucleotides). The control DNA-modified siRNA was designed to have the least homology to human and mouse genes. For the in vitro experiments, DNA-modified siRNAs were synthesized, cartridge-purified, and annealed (Sigma-Aldrich). For the in vivo experiments, DNA-modified siRNAs were synthesized, annealed, and purified using HPLC (ST Pharm., Seoul, Korea). The siRNA transfection in vitro experiment was carried out using Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA) as reported previously,³⁰ except for SNU-1 cells. Because Lipofectamine RNAiMAX was toxic to SNU-1 cells, the cells were exposed to siRNA-Lipofectamine RNAiMAX complex for 4 hours, then centrifuged, resuspended in a complete medium, and cultivated. The siRNA transfection in vivo experiment was undertaken using AteloGene Local Use (Koken, Tokyo, Japan).

2.3 | Cell viability

Water-soluble tetrazolium salt (WST-8) colorimetric assays were carried out using a CCK-8 (Dojin Laboratories, Kumamoto, Japan) according to the manufacturer's protocol. Because the maximum knockdown effects of siRNAs were usually observed 2-3 days after transfection, cells were incubated for 5 days after transfection with siRNAs (4 days after treatment with 5-FU), which was longer than the period described in the manufacturer's protocol (1-3 days), then analyzed using an iMark microplate reader (Bio-Rad, Hercules, CA, USA). The absorbance of the plates was read at wavelengths of 450 and 620 nm.

2.4 | Combination index

Quantification of the mixture of chi*MDM4*/chi*MDM2* and 5-FU synergy was determined by the Chou-Talalay method for drug combination using CalcuSyn software (Biosoft, Cambridge, UK).³¹ A combination index (CI) <0.9 indicates synergism, 0.9-1.1 indicates additivity, and >1.1 indicates antagonism.

2.5 | Immunoblot analysis

Both SDS-PAGE and immunoblot analysis were carried out as previously described.¹⁶ The primary and secondary Abs used in this study were:

mouse mAb against MDM2 (2A10) (Abcam, Cambridge, UK); goat polyclonal Ab against MDMX (D-19) (Santa Cruz Biotechnology, Dallas, TX, USA); anti-TP53 mouse mAb (BP53-12) (Cell Sciences, Canton, MA, USA); mouse mAbs against p21Waf1/Cip1 (DCS60), and rabbit polyclonal Ab against p53 upregulated modulator of apoptosis (PUMA) (Cell Signaling Technology, Danvers, MA, USA); and rabbit polyclonal Ab against β -actin (Medical & Biological Laboratories, Nagoya, Japan). Both HRP-conjugated sheep anti-mouse IgG and donkey anti-rabbit IgG sera were purchased from GE Healthcare (Chicago, IL, USA). The HRP-conjugated rabbit anti-goat IgG was purchased from Sigma-Aldrich. Chemiluminescent detection was carried out using ECL Select Western Blotting Detection Reagent (GE Healthcare) and the Ez-Capture Imaging System (Atto, Tokyo, Japan).

2.6 | Quantitative RT-PCR

RNA samples were extracted from cell lysate using 40 μ L RealTime Ready Cell Lysis reagent (Roche Diagnostics, Mannheim, Germany) per well of a 96-well culture plate, according to the manufacturer's instructions. Complementary DNA was synthesized using 2 μ L RNA and 8 μ L Transcriptor Universal cDNA Master (Roche Diagnostics) in 20- μ L reactions. Quantitative RT-PCR assays were carried out using the Applied Biosystems 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) in 96-well plates. Primer and TaqMan probe for CDKN1A (p21Cip1) and ACTB (β -actin) were obtained from Applied Biosystems (Assay ID: Hs00355782_m1 and Hs99999903_m1, respectively). Reactions were carried out in triplicate under standard thermocycling conditions in a 20 μ L volume containing 5 μ L cDNA, 900 nmol/L primers, 250 nmol/L probe, and 10 μ L TaqMan Gene Expression Master Mix (Applied Biosystems), according to the manufacturer's protocol. The amount of target mRNA was examined and normalized to that of β -actin.

2.7 | Cell cycle assay

Cells were seeded into 60-mm dishes at 1×10^5 /dish. After overnight cultivation, cells were transfected with DNA-modified siRNAs (0.5–2 nmol/L) for 24 hours, then cultured in the presence of 5-FU (4 μ mol/L). After 2 days of cultivation, cells were gently lifted with Accutase (US Biotechnologies, Parker Ford, PA, USA) at room temperature for 10 minutes. The cells were then washed once with PBS and stained with a Cycletest Plus DNA reagent kit (BD Biosciences, Franklin Lakes, NJ, USA), according to the manufacturer's protocol. Flow cytometry was carried out using a FACSCalibur flow cytometer and CellQuest software (both BD Biosciences). The percentage of cells in different cell cycle phases was calculated using ModFit LT software (Verity Software House, Topsham, ME, USA).

2.8 | In vivo antitumor effect of 5-FU plus knockdown of MDM4 and MDM2

All animal experiments were undertaken according to procedures approved by the Institutional Animal Care and Use Committee of the University of Tsukuba (Tsukuba, Japan).

Female BALB/c nude mice (5 weeks old) were obtained from Charles River Japan (Kanagawa, Japan) and maintained under specific pathogen-free conditions in a temperature and humidity-controlled environment. HCT116 cells were suspended in saline solution (Otsuka Pharmaceutical, Tokyo, Japan) at a concentration of 5×10^4 / μ L. One hundred microliters of the adjusted cell suspension of HCT116 was s.c. injected into the right flank of mice under anesthesia. Ten days after inoculation, the s.c. xenografted tumors grew to approximately 50 mm³ in size. The mice were randomly assigned to 4 groups ($n = 5$ per group) as follows: chiCtrl alone (1 mg/kg), mixture of chiMDM4 and chiMDM2 (0.5 mg/kg, each), chiCtrl (1 mg/kg) plus 5-FU (30 mg/kg), and a mixture of chiMDM4 and chiMDM2 (0.5 mg/kg, each) plus 5-FU (30 mg/kg). DNA-modified siRNA was directly injected into tumor once a week (days 0, 7, and 14) using AteloGene as described in the manufacturer's instruction. 5-FU was i.p. injected 3 times a week for 3 weeks (days 1, 4, 6, 8, 11, 13, 15, 18, and 20). Tumor volume was measured with a caliper 3 times a week and calculated using a formula of $V = (\text{length} \times \text{width}^2)/2$. To monitor health, the mice were weighed 3 times a week, and their general physical status was recorded daily. Experiments were terminated before the largest size of tumor reached 2000 mm³.

2.9 | Statistical analysis

Statistical significance of differences between various groups was evaluated using Dunnett's or Tukey's test (in vitro assay). A repeated-measures ANOVA was used to evaluate the in vivo antitumor effects of the drugs. A difference between the experimental groups was considered statistically significant at a P -value of $<.05$. All statistical analyses were undertaken using SPSS version 25.0 (SPSS, Chicago, IL, USA).

3 | RESULTS

3.1 | Cell growth inhibition of MDM4/MDM2 double knockdown and 5-FU in wt TP53 colon and gastric cancer cells

To test if double knockdown of MDM4 and MDM2 could enhance the antitumor activity of 5-FU in colon and gastric cancers with wtTP53/highMDM4, the effect of chiMDM4/chiMDM2 on the growth inhibitory activity of 5-FU was examined by WST-8 assay using 2 colon cancer (HCT116 and LoVo) and 2 gastric cancer (SNU-1 and NUGC-4) cell lines. As shown in Figure 1A, a mixture of chiMDM4 and chiMDM2 in equimolar amounts and 5-FU alone suppressed the growth of HCT116 cells in a dose-dependent manner as compared with control DNA-modified siRNA (chiCtrl). Combination of chiMDM4/chiMDM2 and 5-FU suppressed the growth more than each alone. Similar enhancement of 5-FU-mediated growth suppression by chiMDM4/chiMDM2 was observed in LoVo (Figure 1B), SNU-1 (Figure 1C), and NUGC-4 cells (Figure 1D).




FIGURE 1 Effects of double knockdown of *MDM4* and *MDM2* and 5-fluorouracil (5-FU) on the growth of colon (HCT116 and LoVo) and gastric cancer cell lines (SNU-1 and NUGC-4) with wtTP53/high *MDM4*. HCT116 (A), LoVo (B), SNU-1 (C), and NUGC-4 cells (D) were transfected with either DNA-modified control siRNA (chiCtrl) or mixture of DNA-modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2). After 4–16 hours of incubation, cells were exposed to 5-FU at the indicated concentrations. Five days after transfection, cell viability was determined using the WST-8 assay. Cell viability relative to those transfected with chiCtrl are shown (mean \pm SD; $n = 3$). * $P < .05$, compared with the chiCtrl

TABLE 1 Combination index of mixture of chiMDM4/chiMDM2 and 5-fluorouracil (5-FU)

Cell line	chiMDM4 (nmol/L)	chiMDM2 (nmol/L)	5-FU (4 μmol/L)	Combination index
HCT116	0.250	0.250	+	0.28
	0.500	0.500	+	0.29
LoVo	0.500	0.500	+	0.90
	1.000	1.000	+	0.97
SNU-1	0.125	0.125	+	0.95
	0.250	0.250	+	0.97
NUGC-4	0.500	0.500	+	0.83
	1.000	1.000	+	0.77

Combination index (CI) values were calculated, and they are summarized in Table 1. The CI value of HCT116 cells was lowest (<0.3), followed by NUGC-4 cells (0.83, 0.77), LoVo cells (0.90, 0.97), and SNU-1

cells (0.95, 0.97), showing that *MDM4/MDM2* double knockdown enhanced the antitumor activity of 5-FU synergistically in HCT116 cells and NUGC-4 cells and additively in SNU-1 cells and LoVo cells.




FIGURE 2 Effects of *MDM4* knockdown and nutlin-3 on tumor cell growth and antitumor activity of 5-fluorouracil (5-FU) in colon and gastric cancer cells. A, Growth inhibitory effect of *MDM4* knockdown and nutlin-3 in HCT116 (a), LoVo (b), SNU-1 (c), and NUGC-4 cells (d). Cells were transfected with either control siRNA (chiCtrl) or DNA-modified siRNA targeting *MDM4* (chiMDM4). After 4-16 hours of incubation, cells were exposed to nutlin-3 at the indicated concentrations. Five days after transfection, cell viability was determined using the WST-8 assay. Cell viability relative to those transfected with chiCtrl are shown (mean ± SD; n = 3). B, Enhancement of *MDM4* knockdown/nutlin-3 on antitumor activity of 5-FU in colon (HCT116) and gastric cancer cells (NUGC-4). HCT116 (left) and NUGC-4 cells (right) were transfected with either chiCtrl or chiMDM4. After 16 hours of incubation, cells were exposed to nutlin-3 and 5-FU at the indicated concentrations. Five days after transfection, cell viability was determined using the WST-8 assay. Cell viability relative to those transfected with chiCtrl are shown (mean ± SD; n = 3)

TABLE 2 Combination index of chiMDM4 and nutlin-3

Cell line	Nutlin-3 ($\mu\text{mol/L}$)	chiMDM4 (nmol/L)	Combination index
HCT116	1.00	0.50	0.49
	2.00	0.50	0.31
	5.00	0.50	0.49
	1.00	1.00	0.88
	2.00	1.00	0.72
	5.00	1.00	0.97
LoVo	1.00	1.00	0.48
	2.00	1.00	0.35
	5.00	1.00	0.30
	1.00	2.00	0.51
	2.00	2.00	0.33
	5.00	2.00	0.28
SNU-1	1.00	0.25	0.96
	2.00	0.25	0.82
	5.00	0.25	0.94
	1.00	0.50	0.98
	2.00	0.50	1.04
	5.00	0.50	1.07
NUGC-4	1.00	1.00	0.47
	2.00	1.00	0.23
	5.00	1.00	0.26
	1.00	2.00	0.54
	2.00	2.00	0.53
	5.00	2.00	0.68

We tested whether nutlin-3, an inhibitor of MDM2-p53 interaction, could serve as a substitute for chiMDM2 to enhance the antitumor effect of chiMDM4 in 4 cell lines (NUGC-4, SNU-1, HCT116, and LoVo). As shown in Figure 2A and Table 2, a synergistic antitumor effect of chiMDM4 and nutlin-3 was observed in 3 cell lines (NUGC-4, HCT116, and LoVo), whereas a mostly additive effect was seen in the SNU-1 cell line. Next, we examined whether the combination of chiMDM4/nutlin-3 could enhance the antitumor effect of 5-FU in HCT116 and NUGC-4 cells (Figure 2B, Table 3). We found that chiMDM4/nutlin3 synergistically enhanced the 5-FU effect in HCT116 (CI, 0.55-0.93), whereas its effect was additive or even antagonistic to 5-FU in NUGC-4 (CI, 0.82-1.42).

3.2 | Expression of MDM2, MDM4, p53, and their downstream molecules by MDM4/MDM2 double knockdown

To explore the mechanisms by which chiMDM4/chiMDM2 enhanced 5-FU-mediated growth suppression in colon and gastric cancer cells, expression changes of MDM2, MDM4, p53, p21, and PUMA were examined in 2 colon cancer (HCT116 and LoVo) and 2 gastric cancer cells (SNU-1 and NUGC-4) by immunoblotting (Figure 3). The results of quantification of immunoblotting bands are shown in Table S1.

HCT116 cells are known to have wild and mutant alleles of MDM4. The mutant allele contained 1 base deletion of the third nucleotide of codon 279 and resulted in frameshift and premature termination. This gave rise to a smaller protein of 289 amino acids,³² which retained a p53-binding region and could exert an inhibitory effect toward p53. chiControl-transfected HCT116 cells expressed two bands of 80 and 40 kDa (Figure 4), representing wild and mutant MDM4, respectively.

chiMDM4/chiMDM2 suppressed both wild and mutant MDM4 in HCT116 and NUGC-4 cells by 11- and 10-fold, respectively, which was more efficient than in LoVo (3.8-fold) and SNU-1 cells (1.8-fold). chiMDM4/chiMDM2 also decreased the levels of MDM2 in all cell lines by 1.3 to 3.7-fold. Knockdown of MDM4/MDM2 concomitantly induced the accumulation of p53 and its downstream gene products of p21 and PUMA. The enhancing effects on p53 expression were almost equivalent among the 4 cell lines (2.2 to 3.0-fold).

5-FU increased p53 and its responsive gene products, MDM2, p21, and PUMA to various degrees in cell lines tested here. 5-FU accumulated MDM2 more in NUGC-4 (8.8-fold) and HCT116 cells (4.2-fold) than in LoVo (3.3-fold) and SNU-1 cells (1.4-fold). In contrast, the level of MDM4 was inversely related to that of MDM2, suggesting that MDM4 might be destabilized by induced MDM2 in these cells.

TABLE 3 Combination index of chiMDM4/nutlin-3 and 5-fluorouracil (5-FU)

Cell line	chiMDM4 (nmol/L)	Nutlin-3 (μmol/L)	5-FU (4 μmol/L)	Combination index
HCT116	0.5	2.0	+	0.55
	0.5	5.0	+	0.93
	1.0	2.0	+	0.48
	1.0	5.0	+	0.66
NUGC-4	1.0	2.0	+	0.82
	1.0	5.0	+	1.06
	2.0	2.0	+	1.19
	2.0	5.0	+	1.42




FIGURE 3 Effects of double knockdown of *MDM2* and *MDM4* and 5-fluorouracil (5-FU) on levels of p53, p21, and p53 upregulated modulator of apoptosis (PUMA) in colon (HCT116 and LoVo) and gastric cancer cells (SNU-1 and NUGC-4). HCT116, LoVo, SNU-1, and NUGC-4 cells were transfected with either control siRNA (chiCtrl) or a mixture of DNA-modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2). After 4-16 hours of incubation, cells were exposed to 5-FU at the indicated concentrations. Twenty-four hours after exposure to 5-FU, cells were analyzed for levels of *MDM2*, *MDM4*, p53, p21, and PUMA using immunoblotting. β-actin was used as an internal control




FIGURE 4 Expression level of *MDM4* in wtTP53 colon (HCT116 and LoVo) and gastric cancer cell lines (SNU-1 and NUGC-4). Expression levels of *MDM4* were analyzed by immunoblotting

Treatment with chiMDM4/chiMDM2 plus 5-FU accumulated a lower level of *MDM2* than 5-FU alone. Furthermore, chiMDM4/chiMDM2 plus 5-FU most potently suppressed the level of *MDM4* than either alone in all tested cell lines. As a result, induction of p53 and p21 was highest in these cells treated with chiMDM4/chiMDM2 plus 5-FU compared with cells treated with either alone.

Although both *MDM2* and p21 were products of p53-responsive genes, 5-FU increased the p21 level less than the *MDM2* level in HCT116 and LoVo cells. Therefore, we analyzed p21 mRNA levels in HCT116 cells treated with chiMDM4/chiMDM2, 5-FU alone, and chiMDM4/chiMDM2 plus 5-FU using quantitative RT-PCR (Figure 5). Compared with p21 mRNA levels in chiCtrl-treated cells, 5-FU alone, chiMDM4/chiMDM2 alone, and chiMDM4/chiMDM2 plus 5-FU increased the level of p21 mRNA by 2.4-, 4.1-, and 5.1-fold, respectively. These results suggested that p53 activity was highest in cells treated with chiMDM4/chiMDM2 plus 5-FU, and p21 might be destabilized by increased *MDM2* in cells treated with 5-FU.




FIGURE 5 Effects of double knockdown of *MDM4* and *MDM2* and 5-fluorouracil (5-FU) on the level of *p21* mRNA in HCT116 cells. HCT116 cells were transfected with either control siRNA (chiCtrl) or a mixture of DNA-modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2) for 16 hours and then cultured in the presence of 5-FU. Forty-eight hours after transfection, the cells were analyzed for their *p21* mRNA level using quantitative RT-PCR. *p21* mRNA levels relative to those transfected with chiCtrl are shown. * $P < .05$, compared with the chiCtrl

3.3 | Cell cycle distribution and apoptosis

Effects of chiMDM4/chiMDM2, 5-FU alone, and chiMDM4/chiMDM2 plus 5-FU on the cell cycle distribution and apoptosis of colon cancer and gastric cancer cells were examined by flow cytometry (Figure 6).

In HCT116 cells, chiMDM4/chiMDM2 increased the fraction of the G_1 phase and decreased that of the S phase, showing that *MDM4/MDM2* double knockdown caused G_1 arrest. 5-FU decreased the G_1 phase fraction and increased the S phase fraction, showing that 5-FU caused early S phase arrest. The combination of these enhanced chiMDM4/chiMDM2-induced G_1 arrest, as well as apoptotic cell death detected as sub- G_1 fraction.

In SNU-1 cells and LoVo cells, chiMDM4/chiMDM2 caused G_1 arrest. 5-FU alone caused weak G_1 arrest in LoVo cells but had an undetectable effect on the cell cycle distribution in SNU-1 cells. Simultaneous treatment with chiMDM4/chiMDM2 and 5-FU alone enhanced G_1 arrest. chiMDM4/chiMDM2 plus 5-FU increased the population of apoptotic cells in SNU-1 cells but not in LoVo cells.

In NUGC-4 cells, 5-FU alone as well as chiMDM4/chiMDM2 induced G_1 arrest but not apoptosis. 5-FU and chiMDM4/chiMDM2 decreased the S phase fraction, whereas a combination of these two had a faint change in the S phase fraction. Furthermore, a small increase in the G_1 phase fraction was observed with a combination of 5-FU and chiMDM2/chiMDM4 (5-FU alone, 77%; chiMDM2/chiMDM4 alone, 76%; 5-FU plus chiMDM4/chiMDM2, 80%), suggesting that chiMDM4/chiMDM2 marginally enhanced 5-FU-induced G_1 arrest.

3.4 | In vivo antitumor activity

To test whether chiMDM4/chiMDM2 could inhibit in vivo tumor growth and enhance the antitumor activity of 5-FU, we examined the effects of chiCtrl, chiCtrl plus 5-FU, chiMDM4/chiMDM2, and chiMDM4/chiMDM2 plus 5-FU on the growth of HCT116 xenograft

tumors in mice. chiMDM4/chiMDM2 alone and chiCtrl plus 5-FU slowed the tumor growth rate compared with chiCtrl alone (Figure 7), showing that double knockdown suppressed in vivo tumor growth of wt*TP53*/high*MDM4* colon cancer. 5-FU plus chiMDM4/chiMDM2 most potently inhibited the tumor growth compared with chiCtrl/5-FU and chiMDM4/chiMDM2.

4 | DISCUSSION

5-FU is widely used for chemotherapy in various cancers including colon, stomach, and breast cancer. In our previous study, simultaneous knockdown of *MDM4* and *MDM2* using synthetic DNA-substituted siRNAs (chiMDM4 and chiMDM2) was shown to synergistically suppress the growth of cancer cells with wt*TP53*/high*MDM4*.¹⁶ In this study, we showed that double knockdown of *MDM4* and *MDM2* enhanced the antitumor activity of 5-FU in colon and gastric cancer cells with wt*TP53*/high*MDM4*.

In all cell lines used in this study, 5-FU induces p53 expression and concomitant *MDM2*. Accumulated *MDM2*, functioning as a negative feedback regulator, can compromise p53-mediated antitumor activity in 5-FU-treated cancer cells. In HCT116 cells, 5-FU increased *p21* mRNA and *MDM2* but failed to accumulate p21, suggesting that *MDM2* might antagonize p53-mediated growth inhibition through ubiquitination and destabilization of p21.³³ In this context, *MDM2* knockdown using chiMDM4/chiMDM2 might disrupt these negative effects of *MDM2* on p53- and p21-mediated growth inhibition and potentiate the antitumor activity of 5-FU.

We revealed that chiMDM4-mediated growth inhibition could be synergistically enhanced by nutlin-3, as was observed by chiMDM2.³⁴ However, enhancement of 5-FU antitumor activity by chiMDM4/nutlin-3 was less efficient than that by chiMDM4/chiMDM2. Particularly in NUGC-4 cells, chiMDM4/nutlin-3 was even antagonistic to 5-FU at high concentrations. 5-FU caused




FIGURE 6 Effects of double knockdown of *MDM4* and *MDM2* and 5-fluorouracil (5-FU) on cell cycle distribution of colon (HCT116 and LoVo) and gastric cancer cells (SNU-1 and NUGC-4). HCT116 (top left), LoVo (top right), SNU-1 (bottom left), and NUGC-4 cells (bottom right) were transfected with control siRNA (chiCtrl) or a mixture of DNA-modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2) overnight, then exposed to 5-FU. After overnight cultivation, the cells were analyzed for cell cycle distribution by flow cytometry




FIGURE 7 In vivo antitumor activity of a mixture of DNA-modified siRNA targeting *MDM4* (chiMDM4) and *MDM2* (chiMDM2), 5-fluorouracil (5-FU), and combinations of these two in a xenograft model of HCT116 colon cancer cells. Results are expressed as means \pm SE. * $P < .05$, ** $P < .001$, compared with the control group (those injected with control siRNA [chiCtrl])

MDM2 accumulation in NUGC-4 more intensely than in HCT116 cells. Addition of nutlin-3 to 5-FU-exposed cells may further the increase *MDM2* level, which partially inactivates negative growth signals by direct interactions with p53, p21, RB, and E2F1 in these cells.^{33,35} Small molecules and peptides targeting *MDM2* and *MDM4* have been developed,¹⁸ most of which disrupt *MDM2*-p53 interactions and increase *MDM2* expression, similar to nutlin-3.^{13,36} Thus, *MDM2* knockdown might have some advantages over *MDM2*-p53 inhibitors in the treatment of cancers carrying wtTP53.

The magnitude of enhancement of chiMDM4/chiMDM2 on 5-FU-mediated antitumor activity appears to be related to the magnitude of *MDM4* suppression. 5-FU suppresses *MDM4* in synergistic

responders (HCT116 and NUGC-4) more strongly than in additive responders (SNU-1 and LoVo). It remains unknown how 5-FU decreases *MDM4* levels in these cells. 5-FU might destabilize *MDM4* through the increase of *MDM2* induced by p53 activation because *MDM2* can ubiquitinate and destabilize *MDM4*.³⁷ Furthermore, *MDM4* knockdown by chiMDM4/chMDM2 is more efficient in synergistic responders (HCT116 and NUGC-4) than additive responders (LoVo and SNU-1). The expression level of *MDM4* differs among cell lines (Figure 4). Synergistic responders (HCT116 and NUGC-4) express higher levels of *MDM4* than additive responders (SNU-1 and LoVo). Synergistic responders could be more dependent on *MDM4* expression for their growth and survival than additive

responders.^{38,39} Knockdown efficiency of synthetic siRNA might depend on various factors, including transfection efficiencies of siRNA and RNA-induced silencing complex formation. RNA-induced silencing complex formation could be determined by the abundance of AGO2 protein, Hsc70/Hsp90 chaperone, and endoribonuclease complex, consisting of Trax and Translin.⁴⁰ Factors regulating *MDM4* knockdown efficiency are now being analyzed.

This study shows that 5-FU causes similar p53 accumulation in all colon and gastric cancer cell lines carrying wt*TP53*/high*MDM4*. However, the effect of 5-FU on the cell cycle distribution differs among them: 5-FU causes cell cycle arrest in the early S phase in HCT116 cells, whereas it induces G₁ arrest in LoVo cells and NUGC-4 cells. 5-FU has two independent mechanisms of action.⁴¹⁻⁴³ It blocks DNA replication by inhibiting thymidine synthesis, resulting in cell cycle arrest in the early S phase. It also causes nucleolar stress by being incorporated into ribosomal RNA and interfering in subsequent ribosomal RNA processing. This leads to p53 activation, which induces G₁ arrest and apoptosis. 5-FU might activate p53 more potently in LoVo and NUGC-4 cells than in HCT116 cells. Although inhibition of DNA replication has been reported as the major mechanism of action of 5-FU in most cancer cells, the magnitude of nucleolar stress could vary among cell lines, dependent on the efficiency of fluorouridine incorporation into ribosomal RNA. Although 5-FU causes early S-phase arrest in HCT116 cells, its combination with chi*MDM4*/chi*MDM2* dramatically shifts the effect on cell cycle distribution from early S-phase arrest to G₁ arrest with strong p53 activation. This result suggests that the addition of chi*MDM4*/chi*MDM2* might change the main action mechanism of 5-FU from inhibition of DNA replication to augmented activation of p53.

chi*MDM4*/chi*MDM2* plus 5-FU induced larger populations of apoptotic cells in SNU-1 cells than in LoVo cells. Activated p53 can trigger apoptosis by modulating the expression of genes involved in intrinsic (eg, *PUMA*, *BAX*, and *BCL2*) and extrinsic apoptosis pathways (*FAS-L* and *FAS*).⁴⁴ Inducibility of p53-mediated apoptosis depends on the expression and structures of these genes in individual cell lines. LoVo cells but not SNU-1 cells carry *BAX* mutations,^{45,46} which could be one of the mechanisms by which some cancer cells acquire resistance to p53-triggered apoptosis.

In the present study, we show that *MDM4*/*MDM2* double knockdown inhibits in vivo tumor growth and enhances the anti-tumor effect of 5-FU without any intolerable toxicity. Recent advances in the delivery system for oligonucleotides⁴⁷ could enable chi*MDM4*/chi*MDM2* to be applied to the treatment of wt*TP53*/high*MDM4* tumors. Approximately 50% of human cancers express wt*TP53*,⁴⁸ in some fraction of which wt*TP53* is directly suppressed by *MDM2* alone or *MDM2* combined with *MDM4*. Thus, *MDM2* and *MDM4* are ideal targets of therapy for these tumors. In addition, *MDM2* knockout was shown to suppress the growth of tumors lacking *TP53* alleles by inducing p53-responsive gene through *TP73*-mediated transactivation.⁴⁹ *MDM4*/*MDM2* knockdown can be potentially used for the treatment of cancers lacking p53 expression.

In conclusion, the double knockdown of *MDM4* and *MDM2* enhances in vitro and in vivo antitumor activity of 5-FU toward gastrointestinal cancer with wt*TP53*/high*MDM4*. Combination of siRNAs targeting *MDM4* and *MDM2* and cytotoxic anticancer drugs including 5-FU could be a novel therapeutic strategy for such cancers.

ACKNOWLEDGMENTS

We thank Ms. J. Yamaguchi and Ms. M. Aida for their administrative work.

CONFLICTS OF INTEREST

Authors declare no conflicts of interest for this article.

ORCID

Kenji Yamato  <https://orcid.org/0000-0003-4990-9891>

REFERENCES

1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet*. 2000;355:1041-1047.
2. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med*. 2000;343:905-914.
3. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol*. 2000;18:2938-2947.
4. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol*. 2004;22:23-30.
5. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. *J Clin Oncol*. 2007;25:1670-1676.
6. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. *Nat Rev Cancer*. 2009;9:862-873.
7. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. *Trends Cell Biol*. 2010;20:299-309.
8. Merkel O, Taylor N, Prutsch N, et al. When the guardian sleeps: reactivation of the p53 pathway in cancer. *Mutat Res*. 2017;773:1-13.
9. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. *Mol Cell*. 2006;21:307-315.
10. Gu J, Kawai H, Nie L, et al. Mutual dependence of *MDM2* and *MDMX* in their functional inactivation of p53. *J Biol Chem*. 2002;277:19251-19254.
11. Shvarts A, Steegenga WT, Riteco N, et al. *MDMX*: a novel p53-binding protein with some functional properties of *MDM2*. *EMBO J*. 1996;15:5349-5357.
12. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. *Proc Natl Acad Sci USA*. 2003;100:12009-12014.

13. Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. *Cancer Sci.* 2011;102:605-613.
14. Li Q, Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. *Clin Cancer Res.* 2012;19:34-41.
15. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. p53 as a target for the treatment of cancer. *Cancer Treat Rev.* 2014;40:1153-1160.
16. Hirose M, Yamato K, Endo S, et al. MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation. *Oncoscience.* 2014;1:830-843.
17. Pellegrino M, Mancini F, Luca R, et al. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy. *Cancer Res.* 2015;75:4560-4572.
18. Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical overview of MDM2/X-targeted therapies. *Front Oncol.* 2016;6:7.
19. Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. *J Hematol Oncol.* 2017;10:133.
20. Zhang Q, Zeng SX, Lu H. Targeting p53-MDM2-MDMX loop for cancer therapy. *Subcell Biochem.* 2014;85:281-319.
21. Wachter F, Morgan AM, Godes M, Mourtada R, Bird GH, Walensky LD. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting. *Oncogene.* 2017;36:2184-2190.
22. Blotner S, Chen LC, Ferlini C, Zhi J. Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML. *Cancer Chemother Pharmacol.* 2018;81:597-607.
23. Herting F, Herter S, Friess T, et al. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). *Eur J Haematol.* 2016;97:461-470.
24. Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. *J Hematol Oncol.* 2016;9:50.
25. Valassiadou KE, Stefanaki K, Tzardi M, et al. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. *Anticancer Res.* 1997;17:2571-2576.
26. Danovi D, Meulmeester E, Pasini D, et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. *Mol Cell Biol.* 2004;24:5835-5843.
27. Gilkes DM, Pan Y, Coppola D, Yeatman T, Reuther GW, Chen J. Regulation of MDMX expression by mitogenic signaling. *Mol Cell Biol.* 2008;28:1999-2010.
28. Gunther T, Schneider-Stock R, Hackel C, et al. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. *Mod Pathol.* 2000;13:621-626.
29. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. *Nat Rev Cancer.* 2006;6:909-923.
30. Yamato K, Egawa N, Endo S, et al. Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. *Cancer Gene Ther.* 2011;18:587-597.
31. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Regul.* 1984;22:27-55.
32. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature.* 2012;483:603-607.
33. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. *J Biol Chem.* 2004;279:16000-16006.
34. Hu B, Gilkes DM, Farooqi B, Sebt SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. *J Biol Chem.* 2006;281:33030-33035.
35. Ganguli G, Wasyluk B. p53-independent functions of MDM2. *Mol Cancer Res.* 2003;1:1027-1035.
36. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. *Oncogene.* 2008;27:5303-5314.
37. Pan Y, Chen J. MDM2 promotes ubiquitination and degradation of MDMX. *Mol Cell Biol.* 2003;23:5113-5121.
38. Gembarska A, Luciani F, Fedele C, et al. MDM4 is a key therapeutic target in cutaneous melanoma. *Nat Med.* 2012;18:1239-1247.
39. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. *Cancer Res.* 2006;66:3169-3176.
40. Kobayashi H, Tomari Y. RISC assembly: coordination between small RNAs and Argonaute proteins. *Biochim Biophys Acta.* 2016;1859:71-81.
41. Akpinar B, Bracht EV, Reijnders D, et al. 5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53. *Oncotarget.* 2015;6:43679-43697.
42. Fang F, Hoskins J, Butler JS. 5-Fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs. *Mol Cell Biol.* 2004;24:10766-10776.
43. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. *Nat Rev Cancer.* 2003;3:330-338.
44. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis – the p53 network. *J Cell Sci.* 2003;116:4077-4085.
45. Ku JL, Park JG. Biology of SNU cell lines. *Cancer Res Treat.* 2005;37:1-19.
46. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. *Science.* 1997;275:967-969.
47. Kim HJ, Kim A, Miyata K, Kataoka K. Recent progress in development of siRNA delivery vehicles for cancer therapy. *Adv Drug Deliv Rev.* 2016;104:61-77.
48. Hainaut P, Hernandez T, Robinson A, et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. *Nucleic Acids Res.* 1998;26:205-213.
49. Feeley KP, Adams CM, Mitra R, Eischen CM. Mdm2 is required for survival and growth of p53-deficient cancer cells. *Cancer Res.* 2017;77:3823-3833.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Imanishi M, Yamamoto Y, Wang X, et al. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells. *Cancer Sci.* 2019;110:639–649. <https://doi.org/10.1111/cas.13893>